

# 1 TABLE A2: LIST OF ALL ANALYSED FORMS

Form name	Number of concepts	Annotated concepts	UMLS Coverage
<b>ACCF/AHA ACS Key Data Elements</b>	308	294	94%
<b>ACCF/AHA ACS Key Data Elements - Primary cause of death</b>	3	3	100%
<b>CARDS</b>	109	222	99%
<b>Cardiology admission orders, physicians order sheet</b>	69	75	100%
	489	594	98%
<b>GRACE 2.0 ACS Risk Score</b>	10	10	100%
<b>ASSIGN Cardiovascular Risk Score Version 1.5</b>	11	13	100%
<b>Reynolds Risk Score</b>	8	8	100%
<b>QRISK2 CVD Score</b>	14	14	100%
<b>Framingham Risk Score</b>	7	9	100%
<b>TIMI Risk Score for STEMI</b>	8	8	100%
<b>TIMI Risk Score for UA/NSTEMI</b>	7	7	100%
<b>SCORE</b>	5	5	100%
<b>CRUSADE</b>	8	8	100%
<b>ACTION</b>	8	11	100%
	86	93	100%
<b>GRACE</b>	193	213	97%
<b>ACTION Registry</b>	186	169	88%
<b>STEMI-Register Münster</b>	83	120	98%
<b>Kerala ACS Registry</b>	71	74	94%
<b>Deutsches CPU-Register</b>	157	190	96%
<b>ALKK-PCI Register</b>	146	110	86%
<b>SWEDEHEART</b>	229	202	100%
	1065	1078	94%

<b>Quality assurance Coronary Angiography and Percutaneous Intervention (PCI) - Basic (AQUA)</b>	32	29	97%
<b>Quality assurance Coronary Angiography and Percutaneous Intervention (PCI) -Procedure (AQUA)</b>	15	8	80%
<b>Quality assurance Coronary Angiography and Percutaneous Intervention (PCI) -PCI (AQUA)</b>	19	7	58%
<b>Quality assurance Coronary Angiography and Percutaneous Intervention (PCI) - Coronary Angiography (AQUA)</b>	5	4	80%
<b>Quality assurance Carotid Revascularization - Interventional/Catheter-assisted (PTA and/or Stent) (AQUA)</b>	10	5	70%
<b>AMI Specifications Manual for National Hospital Inpatient Quality Measures</b>	42	28	88%
	123	81	79%
<b>Münster - Labor</b>	22	22	100%
<b>Münster - Echokardiographie Anmeldung</b>	11	10	100%
<b>Münster - Echokardiographie Befund</b>	16	16	100%
<b>Münster - EKG Befund</b>	11	11	100%
<b>Münster - Arztbrief</b>	14	14	100%
<b>Münster - Angiographie Anmeldung</b>	44	51	98%
	118	124	100%
<b>Bremen - Admission form</b>	64	54	98%
<b>Bremen - Herzkatheterbericht</b>	26	25	96%
<b>Bremen - EKG</b>	14	13	93%
<b>Bremen - Labor</b>	19	19	100%
<b>Bremen - Transösophageale Echokardiographie</b>	16	16	100%
<b>Bremen - Transthorakale Echokardiographie</b>	15	15	100%
	154	142	98%
<b>Dresden - Arztbrief</b>	14	14	100%
<b>Dresden - Operationsprotokoll (Herzklappen)</b>	13	10	77%
<b>Dresden - Herzkatheterbericht</b>	14	13	93%
<b>Dresden - Echobericht</b>	15	15	100%
<b>Dresden - Labor</b>	35	35	100%

<b>Dresden - Admission form</b>	54	54	100%
	145	141	95%
<b>Magdeburg - Arztbrief</b>	11	11	100%
<b>Magdeburg - Labor</b>	29	29	100%
<b>Magdeburg - Anamnese</b>	63	61	100%
<b>Magdeburg - Echoanmeldung</b>	7	7	100%
<b>Magdeburg - EKG</b>	8	8	100%
<b>Magdeburg - Herzkatheterbericht</b>	16	15	94%
	134	131	99%
<b>PLATO</b>	514	489	93%
	514	489	93%
<b>ATLAS</b>	310	195	96%
	310	195	96%
<b>[Eligibility] EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)</b>	16	16	100%
<b>[Eligibility] PLATO</b>	7	7	100%
<b>[Eligibility] Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice</b>	8	8	100%
<b>[Eligibility] Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)</b>	7	7	100%
<b>[Eligibility] ATLAS</b>	12	12	100%
<b>[Eligibility] An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome</b>	6	6	100%
<b>[Eligibility] ALPACS</b>	4	4	100%
<b>[Eligibility] Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome</b>	9	9	100%
<b>[Eligibility] Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients</b>	29	29	100%
<b>[Eligibility] Early Use of Rosuvastatin in Acute Coronary Syndromes:</b>	20	20	100%

<b>Targeting Platelet-Leukocyte Interactions</b>			
<b>[Eligibility] A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects (TRILOGY ACS)</b>	16	16	100%
<b>[Eligibility] A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome</b>	22	22	100%
<b>[Eligibility] Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event</b>	23	23	100%
<b>[Eligibility] A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention</b>	16	16	100%
<b>[Eligibility] A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS (HouYi)</b>	16	16	100%
<b>[Eligibility] Patient-Centered Adherence Intervention After Acute Coronary Syndrome (ACS) Hospitalization (MEDICATION)</b>	6	6	100%
<b>[Eligibility] The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)</b>	15	15	100%
<b>[Eligibility] Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event (SWAP)</b>	18	17	94%
<b>[Eligibility] Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI (SWITCHIII)</b>	36	36	100%
<b>[Eligibility] Randomized Investigation of Chest Pain Diagnostic Strategies</b>	22	22	100%
<b>[Eligibility] Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )</b>	29	29	100%
<b>[Eligibility] A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction (ACCOAST)</b>	15	14	93%
<b>[Eligibility] Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes (TIMACS)</b>	10	9	100%
<b>[Eligibility] Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA/OASIS 8)</b>	32	32	100%
<b>[Eligibility] Evaluation of a New Cardiac Biomarker Assay</b>	10	10	100%
<b>[Eligibility] Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography (ROMICAT-II)</b>	35	35	100%
<b>[Eligibility] Perioperative Management of Patients With Coronary Stents Undergoing Noncardiac Surgery (RegistStents)</b>	12	12	100%
<b>[Eligibility] A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention</b>	24	24	100%

<b>(PCI) (CHAMPION PHOENIX)</b>			
<b>[Eligibility] Maintenance of Platelet Inhibition With Cangrelor (Bridge)</b>	9	9	100%
<b>[Eligibility] Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome</b>	28	28	100%
<b>[Eligibility] RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome</b>	10	10	100%
<b>[Eligibility] Risk Markers in the Acute Coronary Syndromes (RACS)</b>	7	7	100%
<b>[Eligibility] Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTEMI-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up</b>	26	26	100%
<b>[Eligibility] Myocardial Ischemia and Transfusion (MINT)</b>	17	17	100%
	572	569	100%
	3710	3637	97%